Announced details
The parties have entered into a master services agreement. HLB Pep will manufacture peptides at its GMP-compliant facilities, and ReproCELL Incorporated will sell them in Japan and global markets under a collaboration arrangement. Capital and personnel relationships are not disclosed.
A Korean biotechnology company with strengths in the development and manufacture of peptide materials and peptide drugs. It provides contract development and manufacturing services (CDMO) for peptides used as active pharmaceutical ingredients (APIs) at its own GMP-compliant manufacturing facilities. Its location, representative, capital and year of establishment are not disclosed.
HLB Pep's own GMP-compliant manufacturing facilities; the location beyond the fact that it is a Korean company is not disclosed
The direct impact on the company's results is expected to be minor. The company will promptly disclose any event that has a material impact.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Neoantigen-derived peptides, Neoantigen detection service “NeoSite” |
| Counterparty | HLB Pep |
| Counterparty overview | A Korean biotechnology company with strengths in the development and manufacture of peptide materials and peptide drugs. It provides contract development and manufacturing services (CDMO) for peptides used as active pharmaceutical ingredients (APIs) at its own GMP-compliant manufacturing facilities. Its location, representative, capital and year of establishment are not disclosed. |
| Relationship with the Company | The parties have entered into a master services agreement. HLB Pep will manufacture peptides at its GMP-compliant facilities, and ReproCELL Incorporated will sell them in Japan and global markets under a collaboration arrangement. Capital and personnel relationships are not disclosed. |
| Contract Date | Entered into on or before 23 March 2026; the specific date is not disclosed |
| Launch date | The commencement of manufacturing and sales was announced on 23 March 2026. The actual service commencement date, and whether this represents a planned or completed start, are not disclosed. |
| Applicable area | Personalized cancer vaccines, T-cell receptor (TCR) therapies, Research on immune cell therapies, Translational research, Treatment design in clinical development |
| Location | HLB Pep's own GMP-compliant manufacturing facilities; the location beyond the fact that it is a Korean company is not disclosed |
| Impact on Business Performance | The direct impact on the company's results is expected to be minor. The company will promptly disclose any event that has a material impact. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide an integrated service covering everything from neoantigen detection through the manufacture of GMP-grade peptides based on the detection results, thereby supporting the research, development and implementation of personalized cancer immunotherapies.